Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:hypoxia-inducible_factor_prolyl_hydroxylase_inhibitor
gptkb:drug |
| gptkbp:ATCCode |
B03XA10
|
| gptkbp:CASNumber |
1000025-07-9
|
| gptkbp:chemicalClass |
pyridine derivative
|
| gptkbp:developer |
gptkb:Akebia_Therapeutics
|
| gptkbp:hasMolecularFormula |
C19H16N4O3
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits prolyl hydroxylase domain enzymes
stabilizes hypoxia-inducible factor |
| gptkbp:PubChem_CID |
25154816
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea hypertension hyperkalemia thromboembolic events |
| gptkbp:status |
approved in Japan
not approved in the United States (as of 2024) |
| gptkbp:synonym |
gptkb:AKB-6548
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
anemia due to chronic kidney disease
|
| gptkbp:bfsParent |
gptkb:Varenzin-CA1
gptkb:Vikarby |
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
vadadustat
|